Sanofi (NASDAQ:SNY) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a strong-buy rating in a report issued on Saturday.

A number of other research firms have also commented on SNY. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. Citigroup began coverage on Sanofi in a research report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Barclays downgraded Sanofi from an “overweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. HSBC reissued a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and an average target price of $62.67.

Sanofi Price Performance

Shares of SNY stock opened at $47.27 on Friday. The firm has a market cap of $115.29 billion, a price-to-earnings ratio of 13.13, a PEG ratio of 1.23 and a beta of 0.45. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12. The company has a quick ratio of 0.29, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The stock has a 50-day moving average price of $48.10 and a 200 day moving average price of $48.68.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SNY. Flagship Harbor Advisors LLC bought a new position in shares of Sanofi during the 4th quarter valued at about $25,000. Financial Consulate Inc. acquired a new stake in Sanofi during the 3rd quarter worth approximately $26,000. Ameritas Advisory Services LLC bought a new position in Sanofi in the second quarter valued at approximately $28,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Sanofi in the third quarter valued at approximately $29,000. Finally, Palisade Asset Management LLC bought a new stake in shares of Sanofi during the third quarter worth $30,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.